198 related articles for article (PubMed ID: 38602053)
1. Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine.
Nössing C; Herek P; Shariat SF; Berger W; Englinger B
Curr Opin Urol; 2024 Jul; 34(4):251-257. PubMed ID: 38602053
[TBL] [Abstract][Full Text] [Related]
2. Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
Liu S; Chen X; Lin T
J Adv Res; 2022 Jul; 39():187-202. PubMed ID: 35777908
[TBL] [Abstract][Full Text] [Related]
3. Novel biomarkers in bladder cancer.
Cheng ML; Iyer G
Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
6. Biology of nonmuscle-invasive bladder cancer: pathology, genomic implications, and immunology.
Dyrskjøt L; Ingersoll MA
Curr Opin Urol; 2018 Nov; 28(6):598-603. PubMed ID: 30138123
[TBL] [Abstract][Full Text] [Related]
7. Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.
Cooley LF; McLaughlin KA; Meeks JJ
Urol Clin North Am; 2020 Feb; 47(1):35-46. PubMed ID: 31757298
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.
Jones RT; Felsenstein KM; Theodorescu D
Urol Clin North Am; 2016 Feb; 43(1):77-86. PubMed ID: 26614030
[TBL] [Abstract][Full Text] [Related]
9. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
10. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer.
Miyamoto DT; Mouw KW; Feng FY; Shipley WU; Efstathiou JA
Lancet Oncol; 2018 Dec; 19(12):e683-e695. PubMed ID: 30507435
[TBL] [Abstract][Full Text] [Related]
11. Precision medicine and bladder cancer heterogeneity.
Ma G; Yang X; Liang Y; Wang L; Li D; Chen Y; Liang Z; Wang Y; Niu H
Bull Cancer; 2018 Oct; 105(10):925-931. PubMed ID: 30243478
[TBL] [Abstract][Full Text] [Related]
12. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
13. A place for precision medicine in bladder cancer: targeting the FGFRs.
di Martino E; Tomlinson DC; Williams SV; Knowles MA
Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
[TBL] [Abstract][Full Text] [Related]
14. Hope and challenge: Precision medicine in bladder cancer.
Su H; Jiang H; Tao T; Kang X; Zhang X; Kang D; Li S; Li C; Wang H; Yang Z; Zhang J; Li C
Cancer Med; 2019 Apr; 8(4):1806-1816. PubMed ID: 30907072
[TBL] [Abstract][Full Text] [Related]
15. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
[TBL] [Abstract][Full Text] [Related]
16. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Lyu X; Wang P; Qiao Q; Jiang Y
BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
[TBL] [Abstract][Full Text] [Related]
17. The molecular limitations of biomarker research in bladder cancer.
Vlachostergios PJ; Faltas BM
World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
[TBL] [Abstract][Full Text] [Related]
18. Clinical Proteomics for Precision Medicine: The Bladder Cancer Case.
Latosinska A; Frantzi M; Vlahou A; Merseburger AS; Mischak H
Proteomics Clin Appl; 2018 Mar; 12(2):. PubMed ID: 28980455
[TBL] [Abstract][Full Text] [Related]
19. A precision, personalized approach to the management of bladder cancer.
Apolo AB; Burger M
Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
[No Abstract] [Full Text] [Related]
20.
Kacew A; Sweis RF
Front Immunol; 2020; 11():575258. PubMed ID: 33224141
[No Abstract] [Full Text] [Related]
[Next] [New Search]